NCT06503783View on ClinicalTrials.gov

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 24, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Breast CancerSolid Tumor
Interventions
DRUG

BL-M17D1

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (2)

Unknown

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY